Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Forde

Showing results (41-50 of 307) with videos related to

Pageof 31
Sort By:
Clinical Immunology and Immunopathology|October 1, 1996
Anti-monocyte cytoplasmic antibodies in granulomatous diseaseA M Forde, C Feighery, J Jackson
The New England Journal of Medicine|August 10, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. ReplyPatrick M Forde, Jonathan Spicer, Nicolas Girard
Current Treatment Options in Oncology|February 15, 2019
Use of Immune Checkpoint Inhibitors in MesotheliomaPatrick M Forde, Arnaud Scherpereel, Anne S Tsao
Journal of Separation Science|October 27, 2007
Performance of R-N(R')-R'' functionalised poly(glycidyl methacrylate-co-ethylene glycol dimethacrylate) monolithic sorbent for plasmid DNA adsorptionMichael K Danquah, Jenny Ho, Gareth M Forde
Annual Review of Medicine|October 26, 2018
PD-1 Blockade in Early-Stage Lung CancerSamuel Rosner, Joshua E Reuss, Patrick M Forde
Cancer|May 7, 2025
Immunotherapy for resectable lung cancerColum Dennehy, Michael R Conroy, Patrick M Forde
British Dental Journal|March 27, 2021
Phone call successM Loh, R Smith, M Forde, et al.
Lung Cancer (Amsterdam, Netherlands)|August 4, 2023
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancerMichael R Conroy, Colum Dennehy, Patrick M Forde
Journal of Thoracic Disease|March 30, 2018
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancerJustin Yeh, Kristen A Marrone, Patrick M Forde
British Dental Journal|March 27, 2021
IV treatment increase?M Loh, R Smith, M Forde, et al.
Pageof 31

Showing results (41-50 of 307) with videos related to

Sort By:
Pageof 31
Clinical Immunology and Immunopathology|October 1, 1996
Anti-monocyte cytoplasmic antibodies in granulomatous diseaseA M Forde, C Feighery, J Jackson
The New England Journal of Medicine|August 10, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. ReplyPatrick M Forde, Jonathan Spicer, Nicolas Girard
Current Treatment Options in Oncology|February 15, 2019
Use of Immune Checkpoint Inhibitors in MesotheliomaPatrick M Forde, Arnaud Scherpereel, Anne S Tsao
Journal of Separation Science|October 27, 2007
Performance of R-N(R')-R'' functionalised poly(glycidyl methacrylate-co-ethylene glycol dimethacrylate) monolithic sorbent for plasmid DNA adsorptionMichael K Danquah, Jenny Ho, Gareth M Forde
Annual Review of Medicine|October 26, 2018
PD-1 Blockade in Early-Stage Lung CancerSamuel Rosner, Joshua E Reuss, Patrick M Forde
Cancer|May 7, 2025
Immunotherapy for resectable lung cancerColum Dennehy, Michael R Conroy, Patrick M Forde
British Dental Journal|March 27, 2021
Phone call successM Loh, R Smith, M Forde, et al.
Lung Cancer (Amsterdam, Netherlands)|August 4, 2023
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancerMichael R Conroy, Colum Dennehy, Patrick M Forde
Journal of Thoracic Disease|March 30, 2018
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancerJustin Yeh, Kristen A Marrone, Patrick M Forde
British Dental Journal|March 27, 2021
IV treatment increase?M Loh, R Smith, M Forde, et al.
Pageof 31